Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CASI
Upturn stock ratingUpturn stock rating

CASI Pharmaceuticals Inc (CASI)

Upturn stock ratingUpturn stock rating
$1.18
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CASI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4Target price
Low$1.09
Current$1.18
high$7.67

Analysis of Past Performance

Type Stock
Historic Profit 81.96%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 18.59M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 1
Beta 0.63
52 Weeks Range 1.09 - 7.67
Updated Date 06/30/2025
52 Weeks Range 1.09 - 7.67
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.54

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -129.05%
Operating Margin (TTM) -163.99%

Management Effectiveness

Return on Assets (TTM) -50.88%
Return on Equity (TTM) -1094.5%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 24384337
Price to Sales(TTM) 0.59
Enterprise Value 24384337
Price to Sales(TTM) 0.59
Enterprise Value to Revenue 0.78
Enterprise Value to EBITDA 0.07
Shares Outstanding 15492800
Shares Floating 6146256
Shares Outstanding 15492800
Shares Floating 6146256
Percent Insiders 43.76
Percent Institutions 23.64

Analyst Ratings

Rating 1
Target Price 4
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CASI Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

CASI Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics and pharmaceutical products in China and throughout the world. Founded to bridge the gap between Western and Chinese pharmaceutical markets, it has evolved into a global company. The company was founded in 1997.

business area logo Core Business Areas

  • Commercial Operations: CASI focuses on commercializing approved pharmaceutical products in China, leveraging its regulatory expertise and distribution network.
  • Drug Development: The company is engaged in the development of a pipeline of innovative drug candidates targeting hematology-oncology and other therapeutic areas.

leadership logo Leadership and Structure

Wei-Wu He, Ph.D., is the Chairman and CEO. The company operates with a functional organizational structure, encompassing research and development, regulatory affairs, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • EVOMELA: A proprietary intravenous formulation of melphalan used as a conditioning treatment prior to stem cell transplantation and for multiple myeloma. CASI holds commercial rights in China. Market share data not readily available. Competitors include generics of melphalan.
  • CNCT-19 (CD19 CAR-T cell therapy): CASI holds rights to develop and commercialize CNCT-19 in Greater China. While approved CAR-T therapies like Yescarta and Kymriah exist, CNCT-19 targets a specific subset of leukemia patients. Competitors include Novartis (Kymriah) and Gilead (Yescarta).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The China market is experiencing rapid growth, driven by increasing healthcare spending and an aging population.

Positioning

CASI Pharmaceuticals aims to establish a strong presence in the Chinese pharmaceutical market by leveraging its strategic partnerships and innovative drug pipeline. It focuses on hematology-oncology.

Total Addressable Market (TAM)

The pharmaceutical market in China is substantial and growing. The TAM for hematology-oncology products is significant, driven by the increasing prevalence of cancer and related diseases. CASI is positioned to capture a portion of this TAM through its marketed products and development pipeline.

Upturn SWOT Analysis

Strengths

  • Strong regulatory expertise in China
  • Established commercial infrastructure in China
  • Strategic partnerships with global pharmaceutical companies
  • Innovative drug pipeline

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on partnerships for drug development
  • Small commercial product portfolio
  • Reliance on the Chinese market

Opportunities

  • Expanding market access in China
  • Acquiring or licensing additional pharmaceutical products
  • Developing novel therapeutics for unmet medical needs
  • Expanding into other Asian markets

Threats

  • Intense competition from established pharmaceutical companies
  • Pricing pressures from government regulations
  • Regulatory changes in China
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • NVS
  • JNJ
  • BMY

Competitive Landscape

CASI is a relatively small player in a highly competitive market dominated by large pharmaceutical companies. Its competitive advantages include its regulatory expertise in China and its partnerships with global pharmaceutical companies. Its disadvantages include its limited financial resources and small commercial product portfolio.

Major Acquisitions

No recent significant acquisition is avialable

  • Year: 2024
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: N/A

Growth Trajectory and Initiatives

Historical Growth: CASI's growth has been driven by the acquisition and commercialization of pharmaceutical products in China and development of their pipeline.

Future Projections: Future growth is dependent on the success of its drug pipeline and commercialization efforts. Consult analyst reports for specific revenue and earnings projections.

Recent Initiatives: Recent initiatives include expanding its commercial team in China, progressing its drug pipeline through clinical trials, and seeking new partnerships to expand its product portfolio.

Summary

CASI Pharmaceuticals operates in a challenging but promising market. Its strength lies in regulatory proficiency within China and strategic alliances. It needs to be mindful of its reliance on partnerships and smaller market share. Future success is linked to pipeline success and expanding commercial reach within Asia.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • CASI Pharmaceuticals Investor Relations
  • SEC Filings
  • Company Press Releases
  • Third party pharmaceutical market research reports

Disclaimers:

This analysis is based on publicly available information and analyst estimates. It should not be considered financial advice. Market share estimates are approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CASI Pharmaceuticals Inc

Exchange NASDAQ
Headquaters -
IPO Launch date 1996-06-11
Chairman & CEO Dr. Wei-Wu He Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 233
Full time employees 233

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.